Novartis to Acquire Tourmaline Bio for $1.4 Billion

BERLIN, Sept 9 – Novartis will acquire Tourmaline Bio for $48 per share, valuing the New York-based biopharmaceutical company at $1.4 billion on a fully diluted basis, the Swiss pharma giant said on Tuesday. Focus […]